. Author manuscript; available in PMC: 2011 Mar 1.

Published in final edited form as: J Nucl Med. 2010 Sep 16;51(10):1600–1607. doi: 10.2967/jnumed.110.077149

TABLE 2.

⁹⁰Y-Ibritumomab Tiuxetan Patient: Cumulated Activity, Organ Mass, Dose Calculated by VSV and 3D-RD, and Relative Differences for Corresponding ROIs

ROI	Cumulated activity (MBq·s)	Mass (g)	Dose for VSV (Gy)	Dose for 3D-RD 10⁸ histories (Gy)	Percentage relative difference with VSV	Voxel-to-voxel ratio mode
Liver	4.02E+07	1,241	2.78	2.77	0.25	0.996 (0.024)
Spleen	1.16E+07	323.1	3.02	3.01	0.13	0.996 (0.023)
Left kidney	3.18E+06	124.7	2.14	2.14	0.09	0.995 (0.023)
Right kidney	3.91E+06	112.4	2.89	2.89	0.17	0.996 (0.027)

Data in parentheses are SDs.